KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2026)

Amneal Pharmaceuticals has reported Capital Leases over the past 9 years, most recently at $54.9 million for Q4 2025.

  • For Q4 2025, Capital Leases fell 3.45% year-over-year to $54.9 million; the TTM value through Dec 2025 reached $54.9 million, down 3.45%, while the annual FY2025 figure was $54.9 million, 3.45% down from the prior year.
  • Capital Leases for Q4 2025 was $54.9 million at Amneal Pharmaceuticals, down from $55.7 million in the prior quarter.
  • Over five years, Capital Leases peaked at $61.6 million in Q2 2021 and troughed at $54.9 million in Q4 2025.
  • A 5-year average of $58.8 million and a median of $59.4 million in 2023 define the central range for Capital Leases.
  • Biggest five-year swings in Capital Leases: skyrocketed 2499.27% in 2021 and later dropped 3.75% in 2025.
  • Year by year, Capital Leases stood at $60.3 million in 2021, then increased by 0.86% to $60.8 million in 2022, then decreased by 3.63% to $58.6 million in 2023, then dropped by 2.86% to $56.9 million in 2024, then dropped by 3.45% to $54.9 million in 2025.
  • Business Quant data shows Capital Leases for AMRX at $54.9 million in Q4 2025, $55.7 million in Q3 2025, and $56.0 million in Q2 2025.